Seroconversion rates following COVID-19 vaccination among patients with cancer.
Adult
Aged
Aged, 80 and over
Antibodies, Viral
/ blood
COVID-19
/ complications
COVID-19 Vaccines
/ administration & dosage
Female
Host-Pathogen Interactions
/ immunology
Humans
Immunogenicity, Vaccine
Immunoglobulin G
/ blood
Male
Middle Aged
Neoplasms
/ complications
Public Health Surveillance
Risk Factors
SARS-CoV-2
/ immunology
Seroconversion
Spike Glycoprotein, Coronavirus
/ blood
Vaccination
COVID-19
cancer
hematologi malignancies
vaccine
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
09 08 2021
09 08 2021
Historique:
received:
06
05
2021
revised:
26
05
2021
accepted:
02
06
2021
pubmed:
17
6
2021
medline:
24
8
2021
entrez:
16
6
2021
Statut:
ppublish
Résumé
As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.
Identifiants
pubmed: 34133951
pii: S1535-6108(21)00285-3
doi: 10.1016/j.ccell.2021.06.002
pmc: PMC8179248
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1081-1090.e2Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests A.V. has received research funding from GlaxoSmithKline, BMS, Janssen, Incyte, MedPacto, Celgene, Novartis, Curis, Prelude, and Eli Lilly and Company, has received compensation as a scientific advisor to Novartis, Stelexis Therapeutics, Acceleron Pharma, and Celgene, and has equity ownership in Stelexis Therapeutics. All other authors declare no competing interests.
Références
Drug Discov Today. 2021 Feb;26(2):593-603
pubmed: 33253920
Cancer. 2017 Mar 1;123(5):841-848
pubmed: 27997703
Ann Oncol. 2021 Jun;32(6):787-800
pubmed: 33746047
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Blood. 2021 Jul 1;137(26):3674-3676
pubmed: 33861315
Nat Commun. 2020 Sep 11;11(1):4541
pubmed: 32917884
Ann Oncol. 2021 Aug;32(8):1053-1055
pubmed: 33932508
Cancer Discov. 2021 Feb;11(2):233-236
pubmed: 33355178
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nat Rev Clin Oncol. 2021 May;18(5):313-319
pubmed: 33723371
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Ann Oncol. 2021 Jan;32(1):113-119
pubmed: 33098994
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Blood. 2006 Oct 1;108(7):2470-5
pubmed: 16763208
J Clin Pathol. 2020 Jul;73(7):366-369
pubmed: 32376714
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
Clin Transplant. 2021 Apr;35(4):e14245
pubmed: 33595145
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Immunol Rev. 2003 Aug;194:39-47
pubmed: 12846806
Blood. 2021 Jan 14;137(2):185-189
pubmed: 33259596
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
Lancet Oncol. 2021 May;22(5):581-583
pubmed: 33812495
Viruses. 2021 Apr 07;13(4):
pubmed: 33916927
Front Cell Dev Biol. 2019 Feb 26;7:23
pubmed: 30863749
Cancer Cell. 2020 Nov 9;38(5):629-646
pubmed: 33049215
Nat Med. 2021 Apr;27(4):568-569
pubmed: 33589821
Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E2950-E2959
pubmed: 29507205
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
Cancer Cell. 2021 Jul 12;39(7):895-896
pubmed: 33894136
J Clin Oncol. 2020 Oct 20;38(30):3538-3546
pubmed: 32795225
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Nat Med. 2020 Aug;26(8):1218-1223
pubmed: 32581323
Clin Infect Dis. 2014 Feb;58(3):309-18
pubmed: 24421306
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Nat Cancer. 2021 Apr;2(4):392-399
pubmed: 34661163
Cancer Cell. 2020 Nov 9;38(5):661-671.e2
pubmed: 32997958
J Hematol Oncol. 2020 Oct 8;13(1):133
pubmed: 33032660
Lancet Haematol. 2021 Jun;8(6):e389-e392
pubmed: 33887255
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Clin Microbiol. 2021 Aug 18;59(9):e0098921
pubmed: 34165323